This federal Project Grant award of $241,944 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research on the pharmacological potential of combined translation and autophagy inhibition in high grade serous ovarian cancer (HGSOC). The research aims to study the efficacy and mechanism of action of two novel natural product compounds, didesmethylrocaglamide (DDR) and phyllanthusmin34 (PHY34), in HGSOC models....
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $151,000.00 to The Medical University of South Carolina to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The research aims to: (1) define the essential genes for the lifecycle of polyploid cancer cells and their daughter cells using a CRISPR-Cas9 screen, and (2) determine the expression of putative markers of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding the role of acetylcarnitine metabolism in promoting chemoresistance in high-grade serous ovarian carcinoma (HGSOC). The $1,373,308 award, effective January 1, 2025 through December 31, 2029, will: 1) map the acetylcarnitine-dependent histone acetylation axis and its contribution to homologous recombination-mediated DNA repair, and 2) investigate...
The National Cancer Institute (NCI) awarded a $127,629 Project Grant (CFDA 93.398 - Cancer Research Manpower) to the President and Fellows of Harvard College, Harvard T.H. Chan School of Public Health, from February 1, 2025 to January 31, 2027. The grant will fund research to elucidate the role of germline and somatic human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor (ICI) monotherapy in patients with non-small cell lung cancer (NSCLC)....
This $127,049 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research by Harvard Medical School to investigate the functional and spatial properties of tumor-specific, tumor-infiltrating CD8 T cells. The key objectives are to: Generate patient-derived xenograft (PDX) mouse models of melanoma to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T cells to control tumor growth. Use one of...
This $1,014,000 project grant from the Defense Health Agency will fund research into targeted therapeutic opportunities for ovarian clear cell, small cell, and endometrioid carcinomas at President And Fellows of Harvard College from May 1, 2023 to April 30, 2027. The grant falls under the Military Medical Research and Development program, which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions. Through this...
This $465,020 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to determine the mechanisms by which chemotherapy used to treat primary ovarian tumors inadvertently activates tumor-associated membrane-anchored serine proteases (MASPs) that promote metastatic tumor dissemination. The research plan will use patient-derived primary human ovarian tumor cells, patient ascites, genetically-defined ovarian tumor cell lines, and preclinical...
The National Cancer Institute awarded a $107,948 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Johns Hopkins University. The overarching goal of this 3-year award is to advance the understanding of ovarian tumorigenesis and develop an accessible, high-performance liquid biopsy for ovarian cancer screening. The grant will fund three specific aims: 1) expanding bioinformatics approaches to study repeat elements in cell-free DNA, 2) developing and testing sensitive...
This Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $122,408 in funding to President and Fellows of Harvard College to conduct research on defining the roles of sequence-non-specific DNA-binding domains in the mammalian SWI/SNF chromatin remodeling complex. The goal is to elucidate how these domains contribute to proper complex assembly, catalytic activity, nucleosome remodeling, and genome-wide targeting in human cell line models. This...
This federal Project Grant award of $539,904.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at the Harvard T.H. Chan School of Public Health to develop "Genomically Informed Morphological Stromal Signatures to Predict Lethal Prostate Cancer." The research project, with a performance period from June 2025 to June 2028, aims to leverage genomic and morphological data to identify novel biomarkers for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $131,600.00 in funding to Harvard T.H. Chan School of Public Health to conduct research aimed at understanding and targeting apoptotic dysregulation in high-grade serous ovarian carcinoma (HGSOC).
The key objectives of the research are to: 1) ascertain apoptotic regulation and pro-survival protein dependence in pre-malignant and malignant stages of HGSOC transformation; 2) assess the efficacy of combining pro-survival protein targeting drugs with first-line chemotherapeutics to enhance tumor cell death in HGSOC patient-derived xenograft (PDX) mouse models; and 3) elucidate how hormone and follicular fluid exposure affects apoptotic regulation in fallopian tube epithelial cells. The research will provide the awardee with the mentorship, laboratory skills, and subject matter expertise to transition into an independent career in gynecological cancer biology research. The award period runs from Sep 14, 2024 to Mar 31, 2027.